Psoriasis Clinical Trial
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Body Mass Index (BMI) of 17 to 40 kg/m2
Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm.
Subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face.
Subjects with pustular psoriasis or erythroderma.
Subjects currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication.
Subjects receiving PUVA within 4 weeks of the first dose of study medication.
Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication.
Subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Vallejo California, , United States
Boston Massachusetts, , United States
Rochester New York, , United States
Stony Brook New York, , United States
Portland Oregon, , United States
Philadelphia Pennsylvania, , United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.